PE20170291A1 - Vacunas contra virus de influenza y usos de las mismas - Google Patents

Vacunas contra virus de influenza y usos de las mismas

Info

Publication number
PE20170291A1
PE20170291A1 PE2017000043A PE2017000043A PE20170291A1 PE 20170291 A1 PE20170291 A1 PE 20170291A1 PE 2017000043 A PE2017000043 A PE 2017000043A PE 2017000043 A PE2017000043 A PE 2017000043A PE 20170291 A1 PE20170291 A1 PE 20170291A1
Authority
PE
Peru
Prior art keywords
influenza
domain
polypeptides
hemagglutinin
influenza viruses
Prior art date
Application number
PE2017000043A
Other languages
English (en)
Inventor
Antonietta Impagliazzo
Jan Wilem Meijberg
Katarina Radosevic
Michelle Wagner
Zhaoqing Ding
Original Assignee
Janssen Vaccines And Prevention B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170291(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines And Prevention B V filed Critical Janssen Vaccines And Prevention B V
Publication of PE20170291A1 publication Critical patent/PE20170291A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a polipeptidos de dominio de tallo de hemaglutinina de influenza multimericos que comprenden al menos un primer y un segundo monomeros de dicho dominio, donde cada monomero comprende: a) un dominio de hemaglutinina de influenza HA1 que comprende un segmento de tallo N-terminal de HA1 unido covalentemente a un segmento de tallo C-terminal de HA1; b) un dominio de hemaglutinina de influenza HA2 unido al segmento C-terminal de HA1; c) los polipeptidos no comprenden sitios de escision de proteasa en la union entre los dominios de HA1 y HA2; y d) los monomeros estan unidos mediante un puente disulfuro. Dichos polipeptidos son utiles en la deteccion, tratamiento o prevencion de la influenza
PE2017000043A 2014-07-10 2015-07-09 Vacunas contra virus de influenza y usos de las mismas PE20170291A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14176459 2014-07-10
US201462062754P 2014-10-10 2014-10-10
EP14195143 2014-11-27
EP15155761 2015-02-19

Publications (1)

Publication Number Publication Date
PE20170291A1 true PE20170291A1 (es) 2017-03-26

Family

ID=55063616

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000043A PE20170291A1 (es) 2014-07-10 2015-07-09 Vacunas contra virus de influenza y usos de las mismas

Country Status (17)

Country Link
US (1) US10117925B2 (es)
EP (1) EP3166963B1 (es)
JP (1) JP7094103B2 (es)
KR (1) KR102463632B1 (es)
CN (1) CN107074912B (es)
AU (1) AU2015286723B2 (es)
BR (1) BR112016030577A8 (es)
CA (1) CA2953451C (es)
CL (1) CL2017000064A1 (es)
EA (1) EA035375B1 (es)
MX (1) MX2017000395A (es)
MY (1) MY182440A (es)
PE (1) PE20170291A1 (es)
PH (1) PH12016502468A1 (es)
SG (1) SG11201610456UA (es)
WO (1) WO2016005482A1 (es)
ZA (1) ZA201700165B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
EP3566714A1 (en) 2011-11-28 2019-11-13 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
AU2013362935B2 (en) 2012-12-18 2018-10-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EA034639B1 (ru) 2013-05-30 2020-03-02 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
PE20170290A1 (es) 2014-07-10 2017-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de influenza y usos de las mismas
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
JP7237344B2 (ja) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用
KR20240042570A (ko) * 2016-09-02 2024-04-02 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
CN107765001B (zh) * 2017-10-24 2020-03-27 中国科学院苏州纳米技术与纳米仿生研究所 禽流感病毒感染或禽流感疫苗免疫分型试剂盒
HUE059545T2 (hu) 2018-01-23 2022-11-28 Janssen Vaccines & Prevention Bv Influenzavírus-vakcinák és alkalmazásaik
WO2019191257A1 (en) * 2018-03-28 2019-10-03 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising hemagglutinin
CN109239355B (zh) * 2018-09-05 2020-08-25 中牧实业股份有限公司 禽流感病毒h9亚型抗体酶联免疫检测试剂盒
BR112021005255A2 (pt) * 2018-09-21 2021-06-29 Board Of Regents Of The University Of Nebraska método de produção e uso de genes para vacina contra a influenza centralizada universal
KR20220057578A (ko) 2019-09-05 2022-05-09 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
GB202004825D0 (en) * 2020-04-01 2020-05-13 Diosynvax Ltd Influenza vaccines
JP2023539771A (ja) * 2020-09-07 2023-09-19 インターベット インターナショナル ベー． フェー． Ｈａ抗体陽性ターゲットのためのｈａステムワクチン
TW202317600A (zh) * 2021-06-23 2023-05-01 潤惠生技股份有限公司 預防多種病毒感染的多價疫苗
WO2023154821A2 (en) * 2022-02-11 2023-08-17 University Of Washington Compositions comprising influenza hemagglutinin stem and method for enhancing cross-protective immunity
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY170607A (en) 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
MY183517A (en) 2009-05-11 2021-02-24 Janssen Vaccines & Prevention Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
JP2013526849A (ja) * 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
WO2012054745A1 (en) * 2010-10-20 2012-04-26 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
CN103906763B (zh) 2011-07-14 2016-10-12 克鲁塞尔荷兰公司 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子
EP3566714A1 (en) * 2011-11-28 2019-11-13 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
EA034639B1 (ru) * 2013-05-30 2020-03-02 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
PE20170290A1 (es) 2014-07-10 2017-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de influenza y usos de las mismas

Also Published As

Publication number Publication date
EA201692467A1 (ru) 2017-05-31
SG11201610456UA (en) 2017-01-27
MX2017000395A (es) 2018-02-08
BR112016030577A2 (pt) 2017-10-31
EP3166963A1 (en) 2017-05-17
JP7094103B2 (ja) 2022-07-01
AU2015286723B2 (en) 2019-11-21
PH12016502468B1 (en) 2017-04-10
JP2017521073A (ja) 2017-08-03
WO2016005482A1 (en) 2016-01-14
CN107074912B (zh) 2021-10-29
CL2017000064A1 (es) 2017-11-10
MY182440A (en) 2021-01-25
US20170189519A1 (en) 2017-07-06
PH12016502468A1 (en) 2017-04-10
AU2015286723A1 (en) 2017-01-12
US10117925B2 (en) 2018-11-06
KR102463632B1 (ko) 2022-11-03
CN107074912A (zh) 2017-08-18
CA2953451C (en) 2023-09-19
KR20170027846A (ko) 2017-03-10
EA035375B1 (ru) 2020-06-03
ZA201700165B (en) 2019-06-26
BR112016030577A8 (pt) 2021-07-20
CA2953451A1 (en) 2016-01-14
EP3166963B1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
PE20170291A1 (es) Vacunas contra virus de influenza y usos de las mismas
PE20170290A1 (es) Vacunas contra virus de influenza y usos de las mismas
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
EA201791735A1 (ru) Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения
EA201490659A1 (ru) Вакцины против вируса гриппа и их применения
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
PH12014501118B1 (en) Influenza virus vaccines and uses thereof
MX2018015755A (es) Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
EA201592306A1 (ru) Вакцины против вируса гриппа и их применения
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
PE20210651A1 (es) Vacunas contra virus de la gripe y usos de las mismas
AR101814A1 (es) Partícula de tipo virus flavivirus
BR122020016505A8 (pt) Método para uso em levantamento de uma região de subsuperfície abaixo de um corpo de água pela detecção de ondas de compressão
EA201590860A1 (ru) Варианты гемагглютинина и нейраминидазы вируса свиного гриппа
MX363464B (es) Vacunas contra influenza h5.
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
BR112017024786A2 (pt) virus oncolíticos recombinantes e usos dos mesmos
EA201892385A1 (ru) Модификация сконструированных полипептидов гемагглютинина вируса гриппа
MX2015010763A (es) Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento.
BR112017005993A2 (pt) derivados de peptídeo inovadores e usos dos mesmos
BR112017004008A2 (pt) polipeptídeo recombinante, sequência de ácido nucleico, célula hospedeira, bionanopartícula, métodos para produção de uma bionanopartícula e para tratamento ou prevenção do vírus da dengue, e, vacina.